| Sign In to gain access to subscriptions and/or personal tools. |
Management of a Patient With a Null Low-Density Lipoprotein Receptor MutationA Case Report1st Cardiology Department, Athens, Greece, genkolovou{at}mail.gr
Laboratory of Molecular Genetics, Department of Science of Nutrition and Dietetics, Harokopio University, Athens, Greece
1st Cardiology Department, Athens, Greece
1st Cardiology Department, Athens, Greece
1st Cardiology Department, Athens, Greece
Laboratory of Molecular Genetics, Department of Science of Nutrition and Dietetics, Harokopio University, Athens, Greece
Pediatric Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece
Department of Clinical Biochemistry, Vascular Disease Prevention Clinics, Royal Free Hospital, Royal Free and University College Medical School, London, United Kingdom
1st Cardiology Department, Athens, Greece A 13-year-old Greek boy with severe dyslipidemia, large tuberous xanthomas over the knees and elbows, Achilles tendon xanthomas, and a bilateral corneal arcus was referred to the Lipid Clinic. He had a supravalvular aortic stenosis, 50% to 60% stenosis of both carotid arteries, and normal coronary arteries. Familial hypercholesterolemia was clinically diagnosed. A V408M null low-density lipoprotein receptor (LDLR) mutation was identified in homozygosity. He responded to lipid-lowering drugs by decreasing total cholesterol by 32%, low-density lipoprotein cholesterol by 33%, and triglyceride levels by 30%. Additional treatment with low-density lipoprotein-apheresis further decreased total cholesterol by 52%, low-density lipoprotein cholesterol by 55%, and triglycerides by 43%. Low-density lipoprotein cholesterol levels between apheresis sessions showed a declining pattern. A significant regression of tuberous xanthomas was noted. A suitable combination of lipid-lowering drugs is effective even in this case of homozygosity for a null LDLR mutation. Furthermore, the coadministration of statins, cholestyramine, and ezetimibe during low-density lipoprotein-apheresis tends to counterbalance the postapheresis relapse in low-density lipoprotein cholesterol levels.
Angiology, Vol. 57, No. 6,
729-732 (2007) |
|||